These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

679 related articles for article (PubMed ID: 29746711)

  • 21. Development of a vancomycin dosing approach for critically ill patients receiving hybrid hemodialysis using Monte Carlo simulation.
    Lewis SJ; Mueller BA
    SAGE Open Med; 2018; 6():2050312118773257. PubMed ID: 29780587
    [TBL] [Abstract][Full Text] [Related]  

  • 22. First-dose and steady-state population pharmacokinetics and pharmacodynamics of piperacillin by continuous or intermittent dosing in critically ill patients with sepsis.
    Roberts JA; Kirkpatrick CM; Roberts MS; Dalley AJ; Lipman J
    Int J Antimicrob Agents; 2010 Feb; 35(2):156-63. PubMed ID: 20018492
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Pharmacokinetics and Pharmacodynamics of Extended-Infusion Cefepime in Critically Ill Patients Receiving Continuous Renal Replacement Therapy: A Prospective, Open-Label Study.
    Philpott CD; Droege CA; Droege ME; Healy DP; Courter JD; Ernst NE; Harger NJ; Foertsch MJ; Winter JB; Carter KE; Van Fleet SL; Athota K; Mueller EW
    Pharmacotherapy; 2019 Nov; 39(11):1066-1076. PubMed ID: 31549737
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Pharmacokinetics and Pharmacodynamics of Extended Infusion Versus Short Infusion Piperacillin-Tazobactam in Critically Ill Patients Undergoing CRRT.
    Shotwell MS; Nesbitt R; Madonia PN; Gould ER; Connor MJ; Salem C; Aduroja OA; Amde M; Groszek JJ; Wei P; Taylor ME; Tolwani AJ; Fissell WH
    Clin J Am Soc Nephrol; 2016 Aug; 11(8):1377-1383. PubMed ID: 27197907
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Antibiotic Dosing for Critically Ill Adult Patients Receiving Intermittent Hemodialysis, Prolonged Intermittent Renal Replacement Therapy, and Continuous Renal Replacement Therapy: An Update.
    Hoff BM; Maker JH; Dager WE; Heintz BH
    Ann Pharmacother; 2020 Jan; 54(1):43-55. PubMed ID: 31342772
    [No Abstract]   [Full Text] [Related]  

  • 26. Target attainment analysis and optimal sampling designs for population pharmacokinetic study on piperacillin/tazobactam in neonates and young infants.
    Chen Y; Lu J; Dong M; Wu D; Zhu Y; Li Q; Chen C; Li Z
    Eur J Clin Pharmacol; 2016 Dec; 72(12):1479-1488. PubMed ID: 27644691
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Optimal dosing of piperacillin-tazobactam for the treatment of Pseudomonas aeruginosa infections: prolonged or continuous infusion?
    Kim A; Sutherland CA; Kuti JL; Nicolau DP
    Pharmacotherapy; 2007 Nov; 27(11):1490-7. PubMed ID: 17963458
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Evaluation and Development of Vancomycin Dosing Schemes to Meet New AUC/MIC Targets in Intermittent Hemodialysis Using Monte Carlo Simulation Techniques.
    Lewis SJ; Mueller BA
    J Clin Pharmacol; 2021 Feb; 61(2):211-223. PubMed ID: 32851685
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Levetiracetam dosing in patients receiving continuous renal replacement therapy.
    Chaijamorn W; Charoensareerat T; Rungkitwattanakul D; Phunpon S; Sathienluckana T; Srisawat N; Pattharachayakul S
    Epilepsia; 2021 Sep; 62(9):2151-2158. PubMed ID: 34247386
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Population pharmacokinetics of piperacillin in plasma and subcutaneous tissue in patients on continuous renal replacement therapy.
    Bue M; Sou T; Okkels ASL; Hanberg P; Thorsted A; Friberg LE; Andersson TL; Öbrink-Hansen K; Christensen S
    Int J Infect Dis; 2020 Mar; 92():133-140. PubMed ID: 31978581
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Population pharmacokinetics of piperacillin/tazobactam in critically ill young children.
    Cies JJ; Shankar V; Schlichting C; Kuti JL
    Pediatr Infect Dis J; 2014 Feb; 33(2):168-73. PubMed ID: 23907263
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Population pharmacokinetics of piperacillin and tazobactam in critically ill patients undergoing continuous renal replacement therapy: application to pharmacokinetic/pharmacodynamic analysis.
    Asín-Prieto E; Rodríguez-Gascón A; Trocóniz IF; Soraluce A; Maynar J; Sánchez-Izquierdo JÁ; Isla A
    J Antimicrob Chemother; 2014 Jan; 69(1):180-9. PubMed ID: 23908259
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Recommended β-lactam regimens are inadequate in septic patients treated with continuous renal replacement therapy.
    Seyler L; Cotton F; Taccone FS; De Backer D; Macours P; Vincent JL; Jacobs F
    Crit Care; 2011; 15(3):R137. PubMed ID: 21649882
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Use of Monte Carlo simulation to optimize antibiotic selection for bloodstream infections caused by Enterobacteriaceae in Shandong Province, China.
    Wang C; Bai Y; Li R; Shen C; Zhang J
    Diagn Microbiol Infect Dis; 2020 Jun; 97(2):115039. PubMed ID: 32253072
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Population pharmacokinetics and pharmacodynamics of piperacillin and tazobactam administered by prolonged infusion in obese and nonobese patients.
    Chung EK; Cheatham SC; Fleming MR; Healy DP; Shea KM; Kays MB
    J Clin Pharmacol; 2015 Aug; 55(8):899-908. PubMed ID: 25823963
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Utilizing Monte Carlo Simulations to Optimize Institutional Empiric Antipseudomonal Therapy.
    Tennant SJ; Burgess DR; Rybak JM; Martin CA; Burgess DS
    Antibiotics (Basel); 2015 Dec; 4(4):643-52. PubMed ID: 27025644
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Optimizing bactericidal exposure for beta-lactams using prolonged and continuous infusions in the pediatric population.
    Courter JD; Kuti JL; Girotto JE; Nicolau DP
    Pediatr Blood Cancer; 2009 Sep; 53(3):379-85. PubMed ID: 19422028
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Pharmacokinetic/pharmacodynamic target attainment of intravenous β-lactam regimens against Gram-negative bacteria isolated in a Brazilian teaching hospital.
    Furtado GH; Cardinal L; Macedo RS; Silva JO; Medeiros EA; Kuti JL; Nicolau DP
    Rev Soc Bras Med Trop; 2015; 48(5):539-45. PubMed ID: 26516962
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Cefepime Population Pharmacokinetics and Target Attainment in Critically Ill Patients on Continuous Renal Replacement Therapy.
    Al-Shaer MH; Philpott CD; Droege CA; Courter JD; Healy DP; Droege ME; Ernst NE; Mueller EW; Peloquin CA
    Antimicrob Agents Chemother; 2021 May; 65(6):. PubMed ID: 33722885
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Effects of i.v. push administration on β-lactam pharmacodynamics.
    Butterfield-Cowper JM; Burgner K
    Am J Health Syst Pharm; 2017 May; 74(9):e170-e175. PubMed ID: 28438821
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 34.